Legal status CA: Schedule II PubChem CID 119025665 UNII 544DR70TN4 Molar mass 397.4 g/mol | CAS Number 1715016-77-5 ChemSpider 32741674 Formula C22H24FN3O3 | |
 | ||
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. Although there is no pharmacological information about MDMB-FUBINACA itself, its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (Ki = 0.14 nM, EC50 = 2.42nM). The structure of MDMB-FUBINACA contains the amino acid 3-methylvaline or tert-leucine methyl ester.
Contents
Side effects
There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold to date. Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.
Legal Status
As of October 2015 MDMB-FUBINACA is a controlled substance in Belarus, Russia, and China.